A popular marketer of handheld ultrasound devices has won FDA approval for an AI-enabled B-line quantification tool for use with patients suspected of having compromised lung function.
The agency, which is charged with preventing fraud, deception and unfair business practices, said Illumina’s acquisition of Grail would stifle competition and innovation in the U.S. market for life-saving cancer tests.
According to CMS, MA plans will see an average payment increase of 3.32% from 2023 to 2024, worth approximately $13.8 billion in increases for next year.
This latest recall is due to a heightened risk that the devices will stop working with no warning. There have been 42 customer complaints reported so far.
Radiologists used an AI tool-building platform to create their model(s), which allows clinicians the opportunity to develop AI models without any prior training in data sciences or computer programming.